Android app Apple app link

Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners

By Yahoo! Finance   |   1 month ago
Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners

Exelixis, Inc. (NASDAQ:EXEL) received an upgrade from Leerink Partners after the STELLAR-303 trial. The firm raised the price target to $48, citing the trial's positive impact on the company's longer-term investment outlook.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.